Inactive Instrument

VectivBio Holding AG Stock

VECT

CH1109007893

Latest news about VectivBio Holding AG

VectivBio Holding AG(NasdaqGS:VECT) dropped from NASDAQ Composite Index	23-07-07	CI
Sector Update: Health Care Stocks Advancing Late Thursday	23-06-29	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	23-06-29	MT
Ironwood Pharmaceuticals, VectivBio Say Tender Offer for VectivBio Shares Completed	23-06-29	MT
Ironwood Pharmaceuticals, Inc. completed the acquisition of VectivBio Holding AG from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others.	23-06-28	CI
VectivBio Says Takeover by Ironwood Pharmaceuticals Approved at Extraordinary Shareholder Meeting	23-06-26	MT
Ironwood Pharmaceuticals Tender Offer for VectivBio Clears Antitrust Waiting Period	23-06-16	MT
VectivBio Holding Ag Approves Amendments to the Articles of Association	23-06-02	CI
Credit Suisse Downgrades VectivBio Holding to Neutral From Outperform on Heels of Announced Sale to Ironwood Pharmaceuticals, Lowers PT to $17 From $22	23-05-23	MT
Piper Sandler Downgrades VectivBio to Neutral From Overweight, Adjusts Price Target to $17 From $25	23-05-23	MT
SVB Securities Downgrades VectivBio to Market Perform From Outperform, Adjusts Price Target to $17 From $30	23-05-23	MT
Health Care Up Slightly as Pfizer Rallies on Weight-Drug Hopes -- Health Care Roundup	23-05-22	DJ
Ironwood Pharmaceuticals to Buy VectivBio for $1 Billion, Enhancing Gastrointestinal Portfolio	23-05-22	MT
Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy	23-05-22	RE
Ironwood Pharmaceuticals to Acquire Switzerland-Based VectivBio for About $1 Billion	23-05-22	MT

More news

Latest transcript on VectivBio Holding AG

Ironwood Pharmaceuticals, Inc., VectivBio Holding AG - M&A Call

23-05-22

More transcripts

Analyst Recommendations on VectivBio Holding AG

Credit Suisse Downgrades VectivBio Holding to Neutral From Outperform on Heels of Announced Sale to Ironwood Pharmaceuticals, Lowers PT to $17 From $22	23-05-23	MT
Piper Sandler Downgrades VectivBio to Neutral From Overweight, Adjusts Price Target to $17 From $25	23-05-23	MT
SVB Securities Downgrades VectivBio to Market Perform From Outperform, Adjusts Price Target to $17 From $30	23-05-23	MT
Piper Sandler Adjusts VectivBio Price Target to $25 From $23, Maintains Overweight Rating	23-04-20	MT
Jefferies Starts VectivBio Holding at Buy With $18 Price Target	22-12-13	MT

More recommendations

Press releases VectivBio Holding AG

VectivBio : Articles of Association of VectivBio Holding AG, as amended - Form 6-K	23-07-17	PU
ALENTIS THERAPEUTICS APPOINTS LUCA SANTARELLI AS CHAIRPERSON	23-06-30	AQ
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals	23-06-26	GL
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT	23-06-06	BU
VectivBio : Invitation to the Extraordinary General Meeting - Form 6-K	23-06-05	PU

More press releases

News in other languages on VectivBio Holding AG

LATE BRIEFING - Unternehmen und Märkte -2-	23-05-22
La biotechnologie helvétique a puisé dans ses réserves en 2022	23-04-25
En Suisse aussi, les introductions en Bourse ont repris au 2e trimestre	21-06-30

More news

VectivBio Holding AG is a holding company based in Switzerland. The Company trough it's subsidiaries operates as a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+24.52%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.34%	233B
NOVARTIS AG	+5.40%	201B
ROCHE HOLDING AG	-10.27%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals